Pharmaceuticals & Therapeutics

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

Once a hospital disinfectant, hypochlorous acid is now a skincare star. Magic Molecule's massive CVS launch signals a major shift in the beauty industry.

Italian biopharma giant Chiesi makes its largest acquisition ever, targeting KalVista's groundbreaking oral HAE drug to reshape patient care and its future.

KCIC's 2025 report shows asbestos filings hitting a new peak, driven by a dramatic rise in talc-related lawsuits and massive jury awards.

Shanghai's Vivacta Bio raises over $50M from top VCs to revolutionize cancer treatment with its pioneering in vivo CAR-T therapy, GT801.

Anika Therapeutics posts strong Q1 results with a 13% revenue jump, but analyst caution lingers over pipeline risks and long-term sustainability.

A new patent for a biomarker-guided therapy offers hope for millions with treatment-resistant depression and extends market exclusivity for decades.

A new FDA-cleared system from Chest Wall Innovations offers both PEEK and titanium implants, promising surgeons unprecedented versatility in treating rib fractures.

With a fourfold revenue jump, China's Yangtze River Pharmaceutical Group isn't just selling drugs; it's exporting a new model of global trust and quality.

New MD Andreas Goppelt brings a bold M&A and digital transformation agenda to OrphaCare, aiming to reshape rare disease patient care globally.

While the global glove industry faced oversupply and price wars, INTCO Medical achieved a four-year revenue high through strategic innovation and expansion.

Genomics' big data and Greywolf's novel drugs unite to develop first-in-class treatments for autoimmune diseases, promising a new era of precision medicine.

A landmark study reveals a hidden genetic cause for a common kidney disease in adults, urging for expanded genetic screening and paving the way for new therapies.

With a solid 2025 behind them, investors are watching Bioventus's Q1 results for signs of continued momentum in innovation and profitability.

Cordis launches the first sirolimus-eluting balloon for peripheral artery disease in Japan, backed by strong 3-year clinical data showing durable results.

With financials improving but competition rising, medical device maker Pulmonx faces a critical audience at the BofA healthcare conference in May.

The pharma giant reports a net loss after a major write-down, but management points to a strong consumer division and a CDMO rebound as signs of recovery.

Promising physician access in seconds, CirrusMD's new model, backed by Quantum Health, tackles the care crisis. But can it overcome virtual care's hurdles?

Kiniksa raises its 2026 ARCALYST forecast after a blowout quarter, using its financial strength to advance a pipeline aimed at redefining pericarditis care.

BRC Therapeutics gets the FDA green light for BRC-002, a novel cannabinoid drug for CRPS, a severe pain condition with no approved US treatments.